TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult diabetic foot syndrome subjects over 18 years of age of any sex~* All stages of diabetic foot syndrome including Wagner stage 5 - Mid-foot gangrene only after appropriate surgical treatment.~* Patients suffering from type 1 or type 2 diabetes mellitus with diabetic foot syndrome.~* Stable metabolic and pharmacological control at recruitment and during the trial period.~* Adequate perfusion of lower limb as measured by HHD and confirmed by APSV.~Exclusion Criteria:~* Non-diabetic foot ulceration (traumatic, thermal ulceration etc)~* Diabetic foot syndrome graded 5 on Wagner's scale - hind foot gangrene only.~* Any pathological state or disease which can affect the development and outcomes of diabetic foot syndrome such as liver cell failure and renal failure~* Severe limb ischemia (by clinical assessment and HHD) unless re-vascularized.~* Presence of slough or sequestrum unless debrided.~* Hemoglobin less than 8 g/dl unless corrected.~* Those receiving NSAIDs, steroids or anti-mitotic drugs.~* Septicemia patients requiring urgent amputation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pedyphar (Type: EXPERIMENTAL): Ointment
- Panthenol (Type: ACTIVE_COMPARATOR): Ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of relapsed or refractory multiple myeloma (MM) or other plasma cell disorder (PCD)~  * At least one previous treatment for MM or PCD required~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy~* At least 3 months~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Calcium ≤ 10.5 mg/dL~* No renal stone formation within the past 5 years for patients who have had curative therapy for a condition associated with the risk of stones (e.g., hyperparathyroidism, bladder dysfunction, obstructive uropathy) OR had a single episode of confirmed urolithiasis~* No calculi in urinary tract confirmed by renal ultrasonography, kidney, ureter, and bladder (KUB) x-ray, or other imaging modality~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No uncontrolled cardiac arrhythmia~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study and for 3 months after study completion~* No osteonecrosis of the jaw~* No history of allergic reaction attributed to compounds of similar chemical or biological composition of calcitriol, paricalcitol, or zoledronate~* No uncontrolled intercurrent illness that would preclude study compliance~* No ongoing or active infection~* No psychiatric illness or social situation that may preclude study compliance~PRIOR CONCURRENT THERAPY:~Chemotherapy~* More than 4 weeks since prior chemotherapy~Endocrine~* More than 4 weeks since prior high-dose steroids~Other~* No other concurrent investigational agents or therapies for multiple myeloma or plasma cell disorders~* No concurrent digoxin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with a current AN defined by DSM-V criteria~* Being female~* Age over or equal to 18 years and less or equal to 40 years~  . For patients under 20 years of age, effective bone maturation (attested by a radiography of the hip)~* Agree to take contraception up to five months after the last injection of denosumab .~* Absence of pregnancy evidenced by an interview and a negative assay of human chorionic gonadotropin (ßhCG).~* Evidence of low BMD determined by Z-score value \< -2 DS (at least one site (lumbar spine or total proximal femur)~* Signing an informed consent.~Exclusion criteria:~* Not affiliated to a social security scheme or not being the beneficiary of such a scheme.~* Severe hepatic cytolysis with transaminase up to 5 times normal.~* Severe dental problems: in case of doubt an assessment by a dentist will be required before inclusion.~* Desire of pregnancy during the two years of follow-up study.~* Disease or treatment potentially responsible for secondary osteoporosis.~* Participant already treated with a molecule known to have an effect on bone~* Diabetes.~* Current hypocalcemia.~* Immunodeficiency.~* Cancer with bone lesions~* Patient on protectice measures (guardianship or trusteeship)~* Hypersensitivity to the active substance or to any of the excipients of Prolia®~* Unable to read and / or write and understand the methodology of the study~* Reporting relationship to the investigator~* Anticipate a long stay outside the region that would prevent compliance with the schedule of visits~* Participation to other biomedical research on health products~* Deprived of liberty~* Breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab subcutaneous injections (Type: ACTIVE_COMPARATOR): The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
- Placebo subcutaneous injections (Type: PLACEBO_COMPARATOR): The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Culture Negative Severe Acute Respiratory Infection in Mexico

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years;~* Willing to provide informed consent; or a legal representative is willing to sign informed consent;~* Intubated due to an independent clinical decision by a clinician responsible for the patient's clinical care and NOT affiliated with the research);~* Meet WHO's SARI definition (modified) - all of the criteria below:~* History of fever, subjective feverishness or measured fever of ≥ 38.0 °C, or hypothermia as defined for Systemic Inflammatory Response Syndrome (SIRS) (\<36.0 °C );~* Cough or other respiratory symptoms, such as rapidly progressing dyspnea;~* Onset within the last 21 days (as long as the clinical condition is considered acute and due to the severity it requires intubation); and~* Requiring hospitalization~Exclusion Criteria:~* Intubated for reasons other than SARI (cardiovascular accident, surgery);~* Known microbiologic diagnosis of SARI or respiratory illness:~* Any contraindication to BAL by bronchoscopy as determined by the treating physician~* Bacterial culture or other microbiologic testing for underlying etiology positive would be excluded;~* In women: Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary total hip replacement~* Patient age less than or equal to 75~* Sufficient bone stock to support prosthesis~Exclusion Criteria:~* Previous hip replacement~* Significant angular/bony deformity~* Active joint sepsis~* Metal allergy~* Renal transplant~* Psychosocial disease~* Neurological disease/musculoskeletal disease that may affect weight-bearing

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): DuoFix HA
- 2 (Type: ACTIVE_COMPARATOR): Porocoat porous coated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility Criteria:~* Scheduled to receive radiation therapy.~* At least 18 years of age.~* Does not meet any standard contraindications for MRI (such as being claustrophobic, having metal objects within the body that cannot be removed or having large tattoos), confirmed by completion of our clinical MRI questionnaire form~* Able to understand and willing to sign an IRB approved written informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI (Type: EXPERIMENTAL): Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Postoperative Nutritional Support in Cardiac Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Absolute lymphocyte count \< 1500~* Albumin \<35 g/L~* Body mass index\<21 kg/m2~* B class of nutritional status according to Subjective Global Assessment~Exclusion Criteria:~* Hepatitis B, C~* Total circulatory arrest~* Absence of informed consent signed~* Chronic liver diseases~* Gastric resection in patient's history~* Physical limitations of normal feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- postoperative nutritional supplements (Type: EXPERIMENTAL): postoperative nutritional supplements in addition to standard hospital diet
- standard hospital diet (Type: PLACEBO_COMPARATOR): patients receiving standard hospital diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory myeloma~* M-protein in serum and/or urine by IMWG criteria.~* Bone marrow plasma cells or plasmacytoma~* Related organ or tissue impairment (CRAB)~* Subjects without detectable M protein are eligible if they have an abnormal serum free light chain ratio (FLC) or if they have at least 10% plasma cells in the bone marrow~Exclusion Criteria:~* Ongoing infection~* Cardiac disease~* Uncontrolled hypertension~* Active liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIW-8962, monoclonal antibody (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Response to BPI in Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 13 years to 60 years old~* Sustained partial-thickness or full-thickness burn greater than 20% and less than 41% TBSA~* Parental consent (if subject is less than 18 years old) or individual (if subject is equal to or older than 18) signed, informed consent.~* Able to start BPI in infusion within 8 hours of burn injury.~Exclusion Criteria:~* Age \> 61.~* Inhalational injury requiring mechanical ventilation.~* Partial and full thickness burns totaling \> 41% total body surface area~* Cardiac dysfunction, defined as the presence of any of the following:~  1. New York Heart Class 3 or 4 heart failure.~ 2. Unstable angina or acute myocardial infarction.~ 3. Left ventricular ejection fraction known to be \< 35%.~* Electrical or lightening induced burn injury or any injury that required cardio-pulmonary resuscitation.~* Concomitant non-burn trauma with an ISS \> 9.~* Non-survivable injury secondary to burn size - patients made DNR or comfort care due to burn size.~* Patients with known causes of immunosuppression:~  1. Known history of HIV/AIDS~ 2. Chronic steroid use for underlying medical conditions (equivalent to 15 mg prednisone/day).~ 3. Active oncolytic therapy for known malignancy~* Known or suspected pregnancy~* Known allergy to rBPI21

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BPI infusion group (Type: EXPERIMENTAL): BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bronchial Hyper-responsiveness in Reflux Cough

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive methacholine challenge test PC20 less than 4mg/ml (Can be previously documented in patients notes within last 4weeks)~* Written informed consent~* Patients with a history of chronic cough (at least 3 months duration), and associated symptoms of gastro-oesophageal reflux~* Male and female subjects of at least 18 yrs of age~* Subjects able to perform satisfactory FEV1 manoeuvres~* Subjects able to understand the study and co-operate with the study procedures~* Subjects who consent to their general practitioner (GP) being informed of their study participation~Exclusion Criteria:~* has had a heart attack in the last three months~* suffers from angina, hypertension or ischaemic heart disease~* has epilepsy for which he/she is taking medication~* FEV1\< 60% predicted~* FEV1\<1.6L~* Female subjects who are pregnant, or lactating, or who are of child bearing potential but are not using contraceptive measures~* Suffering from any concomitant disease which may interfere with study procedures or evaluation.~* A lower respiratory tract infection 4 weeks prior to entry on to study~* Participation in another study (use of investigational product) within 30 days preceding entry on to study.~* Alcohol or drug abuse~* Use of opiates to treat cough 1 week prior to enrollment~* Subjects who are taking Angiotensin Converting Enzymes (ACE) inhibitors.~* Subjects who have significant pathology on most recent chest X-Ray.~* Inability to understand the procedures and the implications of a challenge test~* Patients already taking or have taken in last 4 weeks PPI and H2 receptor antagonist (full acid suppression treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- omeprazole and ranitidine (Type: OTHER): 20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Wounds Utilizing Light

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has 8 weeks venus leg ulcer.~* The ulcer was not better on prior treatment of various medical clinics.~* The patient has diabetic ulcer grade 1 or 2~Exclusion Criteria:~* Patient has severe infection.~* Patient is taking antibiotic~* Patient has ankle brachial index less than 0.7~* Patient is schedule to undergone revascularization surgery 10 weeks before the study~* Patient has photosensitive disease~* Patient has cancer~* Creatinine level is more than 2 mg%~* Patient is taking immunosuppressive medication.~* Pregnant women~* Dialysis patient~* Anaemic patients(less than 9 gr)~* Patient has Albumin level less than 3 mg%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: SHAM_COMPARATOR): The device is emitting a sham light
- 2 (Type: EXPERIMENTAL): The device is emitting curative light

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary Hyperparathyroidism (PHPT)~* Moderate/severe hypercalcaemia (Ca\>2.8mmol/L)~* Positive sestamibi scan demonstrating a cervical parathyroid adenoma~* Adenoma visible on ultrasound scan~Exclusion Criteria:~* Large adenoma (\>15mm)~* Deep adenoma (\>20mm from skin surface~* Familial disease (eg members of MEN-1 families)~* Inability to complete questionnaires in English without making mistakes or needing help with translation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIFU Treatment (Type: OTHER): High Intensity Focused Ultrasound. This is not a comparative study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Exacerbation of COPD With Wireless Telemonitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients treated due to acute exacerbation of COPD at the pulmonary wards of the Turku University Hospital~Exclusion Criteria:~* Those sleeping with a bed partner and not having separate mattresses~* Patients with pacemaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telemonitoring (Type: EXPERIMENTAL): Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Pathologic confirmation of diagnosis of neuroblastoma Surgical resection of primary tumor Symptoms of OMS despite a minimum of one month of steroid therapy Must meet all laboratory criteria to demonstrate adequate organ function -~Exclusion Criteria:~Patients currently receiving systemic chemotherapy for treatment of neuroblastoma Patients with documented active infection Patients who are HIV, Hep B or Hep C positive Organ toxicity from any prior therapy or surgical intervention must be resolved prior to study entry~-

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: OTHER): Single Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues